DCVax Articles
NWBT highlights cost effectiveness of DCVax in view of recent immunotherapy pricing concerns
11 August 2011
"Cancer vaccine revolution" seeing most striking data from Northwest Biotherapeutics, says analyst
29 June 2010
Showing 1-3 of 3 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
